Novo Nordisk Board Faces Major Shakeup Following Shareholder Dispute
Significant boardroom changes are underway at Novo Nordisk as the chair and six independent directors step down following disagreements with the company’s majority shareholder. The pharmaceutical firm will hold an extraordinary meeting to elect new leadership amid competitive pressures in the obesity drug market.
Leadership Exodus at Pharmaceutical Giant
Novo Nordisk is experiencing a substantial boardroom shakeup, with the chair and six independent directors reportedly stepping down following disagreements with the company’s majority shareholder, according to recent reports. The Danish pharmaceutical company, renowned for its weight loss and diabetes medications, is facing significant leadership changes that analysts suggest could reshape its strategic direction.
